2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s. Below, we showcase the highlights of 2024 and offer a preview of what’s to come in 2025.

As the clock struck midnight on New Year’s Eve 2023, the atmosphere at Cure Parkinson’s was tinged with a mixture of optimism and urgency. The organization was not merely welcoming a new year but also the promise of breakthroughs in Parkinson’s research. With the recent publication of results from the phase 2 clinical trial of lixisenatide, excitement coursed through the hallways. “Every day, we inch closer to finding more effective treatments for Parkinson’s,” remarked Dr. Emma Carroll, a leading neurologist in the field. “Our mission is motivated not just by science but by the lives that are affected by this condition.”

2024 Updates from Cure Parkinson’s Supported Clinical Trials

Lixisenatide

In September 2023, preliminary results from the LixiPark phase 2 clinical trial hinted at positive outcomes, but 2024 saw the full publication detailing how lixisenatide significantly slowed the progression of motor symptoms in patients compared to a placebo group. As Dr. Jonathan Reid, one of the trial investigators, noted, “This drug represents a beacon of hope for those living with Parkinson’s. While we temper our enthusiasm with caution, the data is compelling.”

DAPA-PD

In February, Cure Parkinson’s and the Van Andel Institute announced funding for a groundbreaking phase 2 clinical trial of dapansutrile, an anti-inflammatory drug. By targeting brain inflammation, researchers believe dapansutrile could decelerate Parkinson’s progression. Led by Dr. Caroline Williams-Gray at the University of Cambridge, the 12-month study involves 36 participants and aims to gauge both safety and tolerability.

Low-dose Lithium

May brought another hopeful opportunity when Cure Parkinson’s and VAI funded a phase 1b clinical trial investigating low-dose lithium. Traditionally used for bipolar disorder, this mineral may have potential in modifying Parkinson’s disease. “We’re optimistic that this trial may reveal new therapeutic avenues,” said Dr. Thomas Guttuso at the University of Buffalo, who leads the team assessing lithium’s influence on Parkinson’s biology.

Exenatide-PD3 Results

However, not all news was positive. The large-scale phase 3 clinical trial of exenatide, a diabetes medication, failed to meet its primary endpoint, disappointing many in the scientific community. “It’s disheartening, but every trial, successful or not, adds value to what we know about the disease,” remarked Dr. Carroll, who expressed cautious optimism for upcoming results from Cure Parkinson’s funded sub-studies.

2024 Highlights from Cure Parkinson’s Funded Pre-Clinical Research

iLCT Pipeline Research Acceleration Grant Programme

The iLCT Pipeline Research Acceleration Grant Programme took substantial strides in 2024, with new projects exploring novel compounds. Dr. Poonam Thakur from the Indian Institute of Science Education and Research is investigating the neuroprotective qualities of probucol and chlorogenic acid, while Dr. Sinead O’Sullivan and Professor Donato Di Monte study carnosic acid.

CP-6

Meanwhile, research led by Dr. Marco Fazzari at the University of Pittsburgh examines CP-6, a synthetic fatty acid that could hold promise in combating neuroinflammation and oxidative stress. “The outcomes of this research could pave the way for meaningful advancements in treatment protocols,” remarked Dr. Fazzari during a seminar.

iLCT Screening Study

To better understand compounds previously assessed by the iLCT committee, Professor Heather Mortiboys from the University of Sheffield will lead a comprehensive screening study of about 100 evaluated drugs, focusing on vital aspects of Parkinson’s pathology. The findings will be crucial in guiding future clinical trials.

Looking Forward to 2025

Upcoming Clinical Trial Recruitment (ASPro-PD and EJS ACT-PD)

As 2025 unfolds, anticipation builds for the upcoming phase 3 clinical trial of ambroxol (ASPro-PD), set to evaluate its potential in slowing Parkinson’s progression. This UK-wide study aims to recruit 330 participants across various clinical centers. “This could redefine our understanding of how we approach Parkinson’s treatment,” said Dr. Reid.

AZA-PD Clinical Trial Results

Soon after, results from the phase 2 AZA-PD trial, which investigated azathioprine as an immunosuppressant treatment for Parkinson’s, will be disclosed. Dr. Williams-Gray’s team aims to provide insights into how azathioprine interacts with the immune system in Parkinson’s, opening doors to potentially new therapeutic methods.

Quarterly Webinars and Biannual Research Update Meetings

To promote transparency and community involvement, Cure Parkinson’s will resume its quarterly webinars alongside its biannual Research Update Meetings. “We need to keep the public informed and engaged,” asserted Dr. Stott, Cure Parkinson’s Director of Research. The next meeting is slated for March 24, 2025, to discuss what lies ahead in Parkinson’s research.

Research Takeaways from 2024

• The LixiPark trial showcased significant potential for lixisenatide.
• Dapansutrile and low-dose lithium are poised for trial outcomes that could alter treatment approaches.
• Exenatide-PD3 emphasizes the complexity of Parkinson’s research and the need for resilience.

As the year draws to a close, the team at Cure Parkinson’s reflects on an impactful 2024 with the resolve that the fight against this debilitating disease is far from over. Each trial, each study, and each effort is a thread in the intricate tapestry of Parkinson’s research, weaving a narrative of hope and resilience that promises to continue into 2025.

Source: cureparkinsons.org.uk